Citations

Citations to this article as recorded by  

• Correspondence to letter to the editor on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”
  Tiantian Wang, Wenjie Huang, Limin Xia
  Clinical and Molecular Hepatology.2026; 32(3): e405.     CrossRef
• Reply to correspondence on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”
  Lei Wu, Yan Zheng
  Clinical and Molecular Hepatology.2026; 32(3): e445.     CrossRef

Citations

Citations to this article as recorded by  

• Engineering the future of precision cancer immunotherapy: Integrating neoantigen biology, engineered delivery platforms, and clinical translation.
  Muhammad Kamran Khan, M. Imad Khan Khalil, Yunjing Zhuo, Hao Liu, Jiahao Gu, Shiming Wang, Imam Hussain, Yang Liu, Yaseen Hussain, Rashid Khan, Zhenbo Tong, Zahid Hussain, Majid Ali, Muhammad Umar, Salim Ullah, Fu-Gen Wu, Hongtao Xu
  Materials Today Advances.2026; 30: 100808.     CrossRef
• Beyond the single model: Critical considerations for translating HCC triplet immunotherapy from bench to bedside: Letter to the editor on “Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale
  Han Zhuo, Yue Teng, Zhongming Tan
  Clinical and Molecular Hepatology.2026; 32(3): e306.     CrossRef
• Correspondence to letter to the editor on “Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma”
  Hideki Iwamoto, Hironori Koga, Takumi Kawaguchi
  Clinical and Molecular Hepatology.2026; 32(3): e424.     CrossRef